Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT07400536 | A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT | recruiting | Phase 3 | 378 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| May 13, 2026 |
| clinicaltrials |
| NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | active not recruiting | Phase 3 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 27 | May 5, 2026 | clinicaltrials |
| NCT07378098 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia | recruiting | Phase 3 | 254 | JW PharmaceuticalINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT03785288 | Vaginal Cuff Brachytherapy Fractionation Study | recruiting | Phase 3 | 258 | Kara Romano, MDOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix(BEATcc) | completed | Phase 3 | 410 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 8 | Apr 21, 2026 | clinicaltrials |
| NCT07168200 | A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer | recruiting | Phase 3 | 720 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO](ENGOT-EN5) | completed | Phase 3 | 263 | Karyopharm Therapeutics IncINDUSTRY | 10 | Apr 13, 2026 | clinicaltrials |
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 398 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer(innovaTV 301) | completed | Phase 3 | 502 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Feb 24, 2026 | clinicaltrials |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | completed | Phase 3 | 1,060 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Feb 20, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | completed | Phase 3 | 617 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Feb 4, 2026 | clinicaltrials |
| NCT07164534 | A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.(CHOC-LATE) | not yet recruiting | Phase 3 | 316 | Tata Memorial HospitalOTHER_GOV | 0 | Feb 4, 2026 | clinicaltrials |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)(LEAP-001) | completed | Phase 3 | 842 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Feb 2, 2026 | clinicaltrials |
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | recruiting | Phase 3 | 120 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03284866 | HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV(COVENANT) | completed | Phase 3 | 536 | AIDS Malignancy ConsortiumNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT06712472 | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer(RAINBO-RED) | recruiting | Phase 3 | 554 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | completed | Phase 3 | 236 | Radiation Therapy Oncology GroupNETWORK | 4 | Dec 31, 2025 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | terminated | Phase 2 / Phase 3 | 12 | Fudan UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05077215 | Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer | not yet recruiting | Phase 3 | 450 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line(DOMENICA) | active not recruiting | Phase 3 | 260 | ARCAGY/ GINECO GROUPOTHER | 10 | Dec 4, 2025 | clinicaltrials |
| NCT06007586 | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients | completed | Phase 3 | 143 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04865289 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study(LEAP-001) | completed | Phase 3 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | completed | Phase 3 | 89 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04537156 | Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | active not recruiting | Phase 3 | 9,327 | Xiamen UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 3 | 445 | AkesoINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07230626 | SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | not yet recruiting | Phase 3 | 412 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 17, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer | terminated | Phase 2 / Phase 3 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, TorontoOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05862272 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | recruiting | Phase 3 | 1,000 | Sumitomo Pharma Switzerland GmbHINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03728881 | Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial(PRIMAVERA) | completed | Phase 3 | 1,240 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2025 | clinicaltrials |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)(FUTURE II) | completed | Phase 3 | 12,167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2025 | clinicaltrials |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | terminated | Phase 3 | 1,272 | BayerINDUSTRY | 13 | Jul 28, 2025 | clinicaltrials |
| NCT05056402 | An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old | active not recruiting | Phase 3 | 1,382 | Xiamen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT06156514 | Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer(MICHELE) | recruiting | Phase 3 | 140 | National Institute of CancerologíaOTHER_GOV | 1 | May 28, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2026source: clinicaltrials